News | Pulmonary Embolism | October 18, 2019

Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates

Study finds readmitted patients twice as likely to die than patients on their first admission

Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates

Image courtesy of the American Heart Association


October 18, 2019 —­­ Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than nonsmokers, according to new research presented at the CHEST Annual Meeting 2019, Oct. 19-23 in New Orleans. The research will be presented by Kam Sing Ho, M.D., from Mount Sinai St. Luke’s and Mount Sinai West in New York City. 

Pulmonary emboli (PE), or blood clots in the lung, are common and are associated with 100,000 deaths annually. Risk factors include advanced age, surgery, trauma, prolonged immobility, cancer, pregnancy, estrogen therapy, congestive heart failure and defects in blood coagulation factors.

The researchers conducted a retrospective study using the AHRQ-HCUP Nationwide Readmission Database to study the role of smoking in hospital readmissions with a primary diagnosis of PE and a secondary diagnosis of tobacco dependence, also called active smoking.

“Active smokers have a higher hospital readmission rate (34.2 percent) for pulmonary embolism,” stated Ho. “We found that 11 percent of smokers and nearly 9 percent of nonsmokers with PE were readmitted to the hospital within 30 days. The most common cause (13 percent) for readmission was PE. Smoking was an independent predictor associated with higher readmission rate.”

The investigators found that readmitted patients were twice as likely to die than patients on their first admission (6.27 percent vs. 3.16 percent). Smoking was associated with readmission as were female gender, atrial fibrillation, in-hospital oxygen requirement, Medicare insurance and additional illnesses. Private insurance and higher income status were associated with fewer readmissions.

“Previous reports have shown that smoking cessation services are underutilized within the hospital,” commented Ho. “The National Readmission Database provides a platform to identify these correlations. This is an early study with promising results, which we are planning further refine with our own hospital database. In the future, we want to incorporate smoking cessation services for all adults hospitalized with pulmonary emboli.”

Michelle Cao, M.D., member of the American College of Chest Physicians Scientific Presentations and Awards Committee and clinical associate professor at Stanford University, California, addressed the importance of smoking cessation and the next step in implementation: “This study provides an opportunity to evaluate methods of implementing tobacco cessation, in light of possible increased risk of pulmonary embolism in smokers. One of the questions posed is how can we better utilize in- hospital smoking cessation programs as well as outpatient programs. Can this service be driven by primary care providers and/or pulmonologists? Successful smoking cessation programs would have major implications on morbidity, mortality as well as economic burden.”

For more information: www.chestmeeting.chestnet.org


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now